Mirtazapine
- PDF / 141,239 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 33 Downloads / 175 Views
1
Mirtazapine Hyperglycaemia: case report A 37-year-old man developed asymptomatic hyperglycaemia after commencing therapy with mirtazapine. The man, who had a history of major depression and marijuana abuse, was initially receiving venlafaxine following referral from a community mental health service to his primary-care physician. However, he developed urinary symptoms and venlafaxine was stopped. Treatment with mirtazapine 30mg at night [therapeutic indication not clearly stated] was started following a washout period. Approximately 1 week prior to mirtazapine therapy, his fasting blood sugar level was 7.9 mmol/L. After 1 month’s therapy, his fasting blood sugar level was 16.8 mmol/L, increasing to 23.3 mmol/L a week later. Metformin was initiated and, after a random blood sugar level reading of 18.8 mmol/L 10 days later, gliclazide was added. However, his fasting blood sugar levels remained elevated and random blood sugar levels peaked at 30 mmol/L. Mirtazapine was then discontinued after approximately 2 months’ therapy, along with gliclazide, and his blood sugar levels were closely monitored. After 5 days, his fasting blood sugar level had decreased to 9.4 mmol/L and his postprandial blood sugar levels were 6.2–9.3 mmol/L. Chen R, et al. Hyperglycaemia secondary to mirtazapine therapy in a 37-year-old man. Australian and New Zealand Journal of Psychiatry 42: 990-991, No. 11, Nov 801133523 2008 - Australia
0114-9954/10/1231-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 6 Dec 2008 No. 1231
